CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts assign CAMP4 Therapeutics a “Moderate Buy” consensus: seven analysts recommend buying the stock, while two rate it a sell. The average 12-month price target is $8.36, nearly double the reported share price of $4.22.
• Recent analyst actions were mixed: JPMorgan upgraded the stock to “overweight” and raised its target to $9.00, while Zacks Research downgraded it to “strong sell” and Weiss Ratings maintained a sell view.
• Insiders and institutions have been adding shares: company insiders purchased 36,031 shares over the past 90 days, while several investment firms—including SummitTX Capital and EcoR1 Capital—opened new positions.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) have been given an average rating of "Moderate Buy" by the nine brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $8.3571.

Several brokerages have recently weighed in on CAMP. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and raised their price target for the company from $5.00 to $9.00 in a report on Tuesday, June 16th. Chardan Capital set a $6.50 price objective on shares of CAMP4 Therapeutics and gave the company a "buy" rating in a research report on Wednesday, June 10th. Rodman & Renshaw started coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a "buy" rating and a $7.00 price objective for the company. Zacks Research cut shares of CAMP4 Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 15th. Finally, Weiss Ratings downgraded shares of CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, May 21st.

CAMP4 Therapeutics Stock Down 0.5%

CAMP stock opened at $4.22 on Tuesday. CAMP4 Therapeutics has a twelve month low of $1.32 and a twelve month high of $7.75. The firm has a market cap of $219.14 million, a PE ratio of -1.79 and a beta of 0.22. The business has a 50 day moving average of $4.02 and a 200 day moving average of $4.29.

Insiders Place Their Bets

In other CAMP4 Therapeutics news, Director Richard A. Young acquired 16,378 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average cost of $1.65 per share, with a total value of $27,023.70. Following the transaction, the director owned 186,388 shares of the company's stock, valued at $307,540.20. The trade was a 9.63% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last ninety days, insiders have purchased 36,031 shares of company stock valued at $59,451. 21.69% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SummitTX Capital L.P. purchased a new position in CAMP4 Therapeutics in the 1st quarter worth about $1,497,000. EcoR1 Capital LLC purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $1,992,000. Jefferies Financial Group Inc. purchased a new stake in shares of CAMP4 Therapeutics during the 4th quarter valued at about $70,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth approximately $61,000. Finally, Jane Street Group LLC bought a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth approximately $157,000.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source